Nasser A. Al-Tayyar
Research Subjects
Research Interests
Nasser A. Al-Tayyar has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Abdulaziz R. Al Johni
Department of Laboratory at King Fahad Hospital , Madinah , Saudi Arabia
1 shared publication - Abdullah A. Khan Ghyathuddin
Department of Biological Sciences, Faculty of Science, King Abdulaziz University
1 shared publication - Jafar Abdullah Alhamad
Department of Biological Sciences, Faculty of Science, King Abdulaziz University , P.O. Box 80203 , Jeddah , 21589 , Saudi Arabia
1 shared publication - Mikiyas D. Teklemariam
School of Nursing, Department of Midwifery, Addis Ababa University, College of Health Sciences , Addis Ababa , Ethiopia
1 shared publication - Mohammed A. Alghamdi
Department of Biological Sciences, Faculty of Science, King Abdulaziz University , P.O. Box 80203 , Jeddah , 21589 , Saudi Arabia
1 shared publication - Mohsen A. Khormi
Department of Biology, College of Science, Jazan University, Jazan, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Walter de Gruyter GmbH in Open Life Sciences
- Vol. 20 (1) , 20251076
Oncolytic bacteria: A revolutionary approach to cancer therapy
Cancer is one of the most devastating diseases all over the globe, and it is the second worldwide cause of death, exceeded only by cardiovascular diseases. The therapeutic approach to human cancer has evolved significantly and has varied depending on the type and stage of cancer, as well as the general health status of the patient. Despite the advancements in cancer treatment, various challenges persist in the treatment of cancer, including side effects, drug resistance, and incomplete eradication of tumors. The use of oncolytic bacteria (cancer targeting and destroying bacteria) has been identified to have several advantages over the traditional methods of cancer treatment. Several bacterial species have been identified to be used in the treatment of different types of cancers. Oncolytic therapy can be achieved through the use of a naturally occurring and/or genetically modified bacterial species, including Clostridium , Salmonella, Escherichia coli, and Listeria spp. with their toxins, enzymes, biofilms, and secondary metabolites as well as their spores that leads to direct or indirect killing of cancer cells. This review provides some highlights about the biology and therapeutic potential of oncolytic bacteria individually or in combination with other therapeutic approaches against different types of cancers. Besides, the current challenges and future perspectives will be explored.
- 1 January 2025
- Published by Walter de Gruyter GmbH in Open Life Sciences
- Vol. 20 (1) , 20251076
Open AccessOncolytic bacteria: A revolutionary approach to cancer therapy
Cancer is one of the most devastating diseases all over the globe, and it is the second worldwide cause of death, exceeded only by cardiovascular diseases. The therapeutic approach to human cancer has evolved significantly and has varied depending on the type and stage of cancer, as well as the general health status of the patient. Despite the advancements in cancer treatment, various challenges persist in the treatment of cancer, including side effects, drug resistance, and incomplete eradication of tumors. The use of oncolytic bacteria (cancer targeting and destroying bacteria) has been identified to have several advantages over the traditional methods of cancer treatment. Several bacterial species have been identified to be used in the treatment of different types of cancers. Oncolytic therapy can be achieved through the use of a naturally occurring and/or genetically modified bacterial species, including Clostridium , Salmonella, Escherichia coli, and Listeria spp. with their toxins, enzymes, biofilms, and secondary metabolites as well as their spores that leads to direct or indirect killing of cancer cells. This review provides some highlights about the biology and therapeutic potential of oncolytic bacteria individually or in combination with other therapeutic approaches against different types of cancers. Besides, the current challenges and future perspectives will be explored.